| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439720 | European Journal of Cancer | 2018 | 8 Pages |
Abstract
PDTC form a heterogeneous group of patients with usual late-stage diagnosis, low radioactive iodine avidity and frequent metastatic spread. TERT promoter mutations could help to identify patients with high risk of radio-iodine refractoriness.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Christelle de la Fouchardière, Myriam Decaussin-Petrucci, Julien Berthiller, Françoise Descotes, Jonathan Lopez, Jean-Christophe Lifante, Jean-Louis Peix, Anne-Laure Giraudet, Armelle Delahaye, Sandrine Masson, Claire Bournaud-Salinas,